natgillin/translations-raw huggingface dataset:
In clinical studies, no serious adverse reactions were attributed to the combination of afoxolaner and milbemycin oxime.
V kliničnih študijah niso bili ugotovljeni nobeni resni neželeni učinki kombinacije učinkovin afoksolaner in milbemicin oksim.
In clinical studies, no serious adverse reactions were attributed to the combination of afoxolaner with milbemycin oxime.
V kliničnih študijah niso bili ugotovljeni nobeni resni neželeni učinki kombinacije učinkovin afoksolaner in milbemicin oksim.
In clinical studies, oral doses of 10-30 mg/day of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan).
V kliničnih raziskavah peroralni odmerki od 10 do 30 mg aripiprazola na dan niso pomembno vplivali na presnovo substratov CYP2D6 (na razmerje dekstrometorfan/3-metoksimorfinan), CYP2C9 (varfarin), CYP2C19 (omeprazol) ali CYP3A4 (dekstrometorfan).
In clinical studies, patients had a LVEF  50% at baseline.
V kliničnih študijah so imeli bolniki izhodiščni LVEF  50 %.
In clinical studies, patients received Lymphoseek up to 30 hours before surgery.
V kliničnih študijah so bolniki zdravilo Lymphoseek prejeli do 30 ur pred kirurškim posegom.
In clinical studies, patients received prophylactic acetylsalicylic acid or alternative anti-thrombotic therapy.
V kliničnih študijah so bolniki profilaktično prejemali acetilsalicilno kislino ali alternativno antitrombotično zdravljenje.
In clinical studies, patients with CrCl (creatinine clearance)  60 mL/min were included and treated at the recommended dose.
V klinične študije so bili vključeni bolniki z OK (očistek kreatinina) >60 ml/min, ki so bili tudi zdravljeni s priporočenim odmerkom.
In clinical studies, patients with creatinine clearance of  45 mL/min required no dose adjustments other than those recommended for all patients.
V kliničnih študijah bolniki z očistkom kreatinina  45 ml/min niso potrebovali prilagajanja odmerkov, razen tistih prilagoditev, ki jih priporočamo za vse bolnike.
In clinical studies, patients with recent or ongoing clinically significant gastrointestinal disorder (e.g., severe vomiting and/or diarrhea) were excluded.
Bolniki z nedavnimi ali prisotnimi klinično pomembnimi boleznimi prebavil (npr. hudo bruhanje in/ali diareja) so bili iz kliničnih študij izključeni.
In clinical studies, patients with severe renal impairment (creatinine clearance < 30 ml/min) or receiving dialysis were at greater risk of developing hypocalcaemia in the absence of calcium supplementation.
V kliničnih študijah so ugotovili, da je tveganje za pojav hipokalciemije brez dodajanja kalcija večje pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) in bolnikih na dializi.
In clinical studies, patients with uncontrolled or significant cardiac disease (e.g. recent myocardial infarction, congestive heart failure, unstable angina or clinically significant bradycardia) were excluded.
V kliničnih študijah so bile neurejene ali klinično pomembne bolezni srca (kot so nedavni miokardni infarkt, kongestivno srčno popuščanje, nestabilna angina pektoris ali klinično pomembna bradikardija) izključitveni kriterij.
In clinical studies, patients with uncontrolled or significant cardiac disease (e.g., recent myocardial infarction, congestive heart failure or unstable angina) were excluded.
Bolniki z nenadzorovanimi ali hudimi srčnimi boleznimi (npr. nedavni miokardni infarkt, kongestivno srčno popuščanje ali nestabilna angina pektoris) so bili iz kliničnih študij izključeni.
In clinical studies, post-mortem examination of the injection sites performed in sows at most 50 days after the vaccination revealed limited lesions such as a discoloration and a granuloma in the majority of animals as well as necrosis or fibrosis (in approximately half of the animals).
Preiskave na mestu dajanja cepiva post mortem pri svinjah največ 50 dni od cepljenja so pokazale omejene spremembe kot je sprememba barve tkiva in granulomi na mestu dajanja pri večini živali, kakor tudi nekroze ali fibroze pri približno polovici živali.
In clinical studies, Rapiscan was administered to patients taking other cardioactive medicinal products (i.e., β-blockers, calcium channel blockers, ACE inhibitors, nitrates, cardiac glycosides, and angiotensin receptor blockers) without apparent effects on the safety or efficacy profile of Rapiscan.
V kliničnih študijah so zdravilo Rapiscan dajali bolnikom, ki so uporabljali druga zdravila za bolezni srca (tj. zaviralce adrenergičnih receptorjev beta, zaviralce kalcijevih kanalčkov, inhibitorje ACE, nitrate, kardiotonične glikozide in zaviralce receptorjev angiotenzina) brez vidnih učinkov na profil varnosti in učinkovitosti zdravila Rapiscan.
In clinical studies, rare cases of anaphylactic reactions have been observed in patients receiving Cosentyx.
V kliničnih študijah so pri bolnikih, ki so prejemali zdravilo Cosentyx, v redkih primerih opažali anafilaktične reakcije.
In clinical studies, riociguat has shown to augment the hypotensive effects of PDE 5 inhibitors.
V kliničnih študijah se je pokazalo, da riociguat poveča hipotenziven učinek zaviralcev PDE5.
In clinical studies, serious bacterial, fungal, and viral infections have been observed in patients receiving STELARA (see section 4.8).
V kliničnih študijah so pri bolnikih, ki so prejemali zdravilo STELARA, opažali resne bakterijske, glivične in virusne okužbe (glejte poglavje 4.8).
In clinical studies, serious infusion and hypersensitivity reactions affected approximately 0.9% of patients, and included anaphylactic reaction, bradycardia, hypotension, angioedema, and dyspnea.
V kliničnih študijah so se resne infuzijske in preobčutljivostne reakcije pojavile pri približno 0,9 % bolnikov; obsegale so anafilaktično reakcijo, bradikardijo, hipotenzijo, angioedem in dispnejo.
In clinical studies, serum transaminase elevations occurred during treatment and up to 4 months after the last dose of Zinbryta.
V kliničnih študijah so se med zdravljenjem in še do 4 mesece po zadnjem odmerku zdravila Zinbryta pojavila povišanja serumskih transaminaz.
In clinical studies, siltuximab was associated with an infusion related reaction or hypersensitivity reaction in 4.8% (severe reaction in 0.8%) of patients treated with siltuximab monotherapy.
V kliničnih študijah je bil siltuksimab povezan z infuzijsko reakcijo ali preobčutljivostjo pri 4,8% (s hudo obliko pri 0,8%) bolnikov, ki so prejemali siltuksimab v monoterapiji.
In clinical studies, tadalafil (5, 10 and 20 mg) was shown to augment the hypotensive effects of nitrates.
V kliničnih študijah so ugotovili, da tadalafil (5, 10 in 20 mg) okrepi hipotenzivne učinke nitratov.
In clinical studies, the [90Y]-radiolabelled Zevalin after pretreatment with rituximab results in a significant radiation dose to the testes.
V kliničnih študijah je povzročilo z [90Y] označeno zdravilo Zevalin po predhodnem zdravljenju z rituksimabom znatne odmerke sevanja na testise.
In clinical studies, the average olanzapine exposure was approximately 27 % higher in adolescents.
V kliničnih študijah je bila povprečna izpostavitev povprečna 27 % višja pri mladostnikih.
In clinical studies, the concomitant administration of Rapamune and HMG-CoA reductase inhibitors and/or fibrates was well-tolerated.
V kliničnih študijah so bolniki dobro prenašali sočasno uporabo zdravila Rapamune in zaviralcev reduktaze HMG-CoA in/ali fibratov.
In clinical studies, the dulaglutide safety profile in patients with moderate renal impairment was similar to the overall type 2 diabetes population.
V klinični študiji je bil varnostni profil dulaglutida pri bolnikih z zmerno okvaro ledvic podoben skupni populaciji s sladkorno boleznijo tipa 2.
In clinical studies, the following undesirable effects have been reported: Common reported side effects included:
V kliničnih študijah so poročali o naslednjih neželenih učinkih v zvezi z zdravilom Osigraft: Pogosti neželeni učinki so bili:
In clinical studies, the incidence of important elevations in creatine phosphokinase (CK ≥ 3 times the ULN, < 5 times the ULN) was 1.92% for patients treated with Pravafenix.
Med bolniki, ki so v kliničnih študijah prejemali zdravilo Pravafenix, je incidenca pomembnih zvišanj kreatin- fosfokinaze (KF ≥ 3-kratnika ZMN < 5-kratnika ZMN) znašala 1,92 %.
In clinical studies, the most commonly reported adverse events were reactions at the injection site, including redness, swelling and pain.
Najpogostejši neželeni učinki, o katerih so poročali v kliničnih študijah, so bile reakcije na mestu injiciranja, vključujoč rdečino, oteklino in bolečino.
In clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.
V kliničnih študijah hidroklorotiazid ni vplival na farmakokinetiko irbesartana.
In clinical studies, the safety and efficacy of amprenavir have not yet been established in children below four years of age.
Varnost in učinkovitost amprenavirja pri otrocih, mlajših od 4 let, še nista dokazani s kliničnimi študijami.
In clinical studies, the safety profile of Pandemic influenza vaccine H5N1 MedImmune was comparable to the safety profile of the seasonal vaccines T/LAIV and Fluenz Tetra (see section 5.1 for more information).
V kliničnih študijah je bil varnostni profil Cepiva proti pandemski gripi H5N1 MedImmune primerljive z varnostnim profilom sezonskih cepiv T/LAIV in Fluenz Tetra (za več informacij glejte poglavje 5.1).
In clinical studies, there were no reports of anaphylaxis.
V kliničnih študijah niso poročali o pojavu anafilaksije.
In clinical studies, treatment with SPRYCEL was continued until disease progression or until no longer tolerated by the patient.
V kliničnih študijah je zdravljenje z zdravilom SPRYCEL trajalo, dokler bolezen ni napredovala oziroma dokler je bolnik zdravljenje prenašal.
In clinical studies, undesirable dopaminergic adverse reactions, e.g. dyskinesia, were more common in patients who received entacapone and dopamine agonists (such as bromocriptine), selegiline or amantadine compared to those who received placebo with this combination.
V kliničnih raziskavah so bili neželeni dopaminergični učinki (npr. diskinezija) pogostejši pri bolnikih, ki so prejemali entakapon in agoniste dopamina (kot je bromokriptin), selegilin ali amantadin, kot pa pri tistih, ki so prejemali to kombinacijo s placebom.
In clinical studies, urticaria and rare cases of anaphylactic reaction to Cosentyx were observed (see also section 4.4).
V kliničnih študijah so opažali pojavljanje urtikarije in redke primere anafilaktične reakcije na zdravilo Cosentyx (glejte tudi poglavje 4.4).
In clinical studies, various formulations of fosaprepitant have been administered to a total of 2,687 individuals including 371 healthy subjects and 2,084 patients with chemotherapy induced nausea and vomiting (CINV).
V kliničnih študijah je različne farmacevtske oblike fosaprepitanta prejelo 2.687 posameznikov, vključno s 371 zdravimi osebami in 2.084 bolniki s s kemoterapijo povzročenima navzeo in bruhanjem (CINV - chemotherapy induced nausea and vomiting).
In clinical study CIR 217 the safety, infectivity, and immunogenicity of a live attenuated, vaccine derived from A/Vietnam/1203/2004 (H5N1) influenza isolate were evaluated in 21 subjects who received one 106.7 median tissue culture infectious dose (TCID50) , with 18 of those subjects receiving a second dose 4-8 weeks later.
V klinični študiji CIR 217 so varnost, infektivnost in imunogenost živega oslabljenega cepiva, pridobljenega iz izolata gripe A/Vietnam/1203/2004 (H5N1), ocenili pri 21 preiskovancih, ki so prejeli en 106,7 median infektivni odmerek tkivne kulture (TCID50); 18 od teh preiskovancev je od 4 do
In clinical study D9902B (IMPACT), 237 out of the 512 patients randomized were evaluated for the development of humoral or cellular immune responses (T cell proliferation and gamma-interferon (γIFN) ELISPOT) to the target antigens at baseline, and at Weeks 6, 14, and 26.
V klinični študiji D9902B (IMPACT) je bilo ocenjenih 237 od 512 randomiziranih bolnikov glede razvoja humoralnega ali celičnega imunskega odgovora (proliferacija T-celic in gama-interferona (γIFN) ELISPOT) v ciljne antigene ob izhodišču, in v 6., 14. in 26. tednu.
In clinical study GS-US-216-0114, a phase 3 randomised, active-controlled clinical study, in which 692 treatment-naïve patients received at least one dose of atazanavir boosted with cobicistat (n = 344) or atazanavir boosted with ritonavir (n = 348) administered with other antiretroviral medicinal products, the most frequently reported adverse reactions in the atazanavir boosted with cobicistat group during 144 weeks were associated with elevated bilirubin levels (see Table 2).
V randomizirani, z zdravilno učinkovino nadzorovani klinični študiji 3. faze GS-US-216-0114, v kateri je 692 predhodno nezdravljenih bolnikov prejelo vsaj en odmerek atazanavirja, okrepljenega s kobicistatom (n = 344), ali vsaj en odmerek atazanavirja, okrepljenega z ritonavirjem (n = 348), sočasno z drugimi protiretrovirusnimi zdravili, so v skupini, ki je prejemala atazanavir, okrepljen s kobicistatom, med 144 tedni zdravljenja najpogosteje poročali o neželenih učinkih, ki so bili povezani z zvišanjem vrednosti bilirubina (glejte tabelo 2).
In clinical study MI-CP217 the safety and descriptive immunogenicity of a live attenuated monovalent influenza virus vaccine (derived from A/California/7/2009) developed for the 2009 H1N1 pandemic were evaluated in a total of 326 randomised subjects (259 subjects monovalent vaccine; 65 subjects placebo) and 324 subjects received one dose of investigational product.
V klinični študiji MI-CP217 so varnost in opisno imunogenost živega oslabljenega monovalentnega cepiva proti virusu gripe (pridobljenem iz A/California/7/2009), razvitega za pandemijo H1N1 2009, ocenili pri skupaj 326 randomiziranih preiskovancih (259 jih je prejelo monovalentno cepivo, 65 placebo) in 324 preiskovancev je prejelo en odmerek raziskovanega cepiva.
In clinical trial studies with rotigotine, syncope has been observed at a rate that was similar to that observed in patients treated with placebo.
V kliničnih preskušanjih z rotigotinom so opazili sinkopo, katere pogostnost je bila podobna kot pri bolnikih, ki so prejemali placebo.
In clinical trials (HPV-070 and HPV-048) performed in girls aged 9 to 14 years receiving a 2-dose schedule (0, 6 months or 0, 12 months) and young women aged 15-25 years receiving Cervarix according to the standard 0, 1, 6 months schedule, all subjects seroconverted to both HPV types 16 and 18 one month after the second dose.
V kliničnih študijah (HPV-070 in HPV-048), izvedenih pri deklicah starih od 9 do 14 let, ki so cepljene po shemi z dvema odmerkoma (0 in 6 mesecev ali 0 in 12 mesecev) in mladih ženskah starih od 15 do 25 let, ki so prejele Cervarix skladno s standardno shemo 0, 1 in 6 mesecev, se je 1 mesec po drugem odmerku pojavila serokonverzija za HPV tipa 16 in 18 pri vseh osebah.
In clinical trials 69 patients who relapsed or were refractory to initial treatment (zoledronic acid 4 mg, 8 mg or pamidronate 90 mg) were retreated with 8 mg zoledronic acid.
V kliničnih preskušanjih je bilo 69 bolnikov, pri katerih se je bolezen ponovno pojavila ali se niso odzvali na začetno zdravljenje (zoledronska kislina 4 mg, 8 mg ali pamidronat 90 mg), ponovno zdravljenih z 8 mg zoledronske kisline.
In clinical trials 69 patients who relapsed or were refractory to initial treatment (zoledronic acid 4 mg, 8 mg or pamidronate 90 mg) were retreated with zoledronic acid 8 mg.
V kliničnih preskušanjih je bilo 69 bolnikov, pri katerih se je bolezen ponovno pojavila ali so bili odporni proti začetnemu zdravljenju (zoledronska kislina 4 mg, 8 mg ali pamidronat 90 mg), ponovno zdravljenih z 8 mg zoledronske kisline.
In clinical trials a thin layer of Raplixa produced doses that typically ranged from 0.3 to 2 g.
V kliničnih preskušanjih je bil odmerek s tanko plastjo zdravila Raplixa običajno med 0,3 do 2 g.
In clinical trials adverse events seen on abrupt treatment discontinuation occurred in approximately 45% of patients treated with Duloxetine Lilly and 23% of patients taking placebo.
V kliničnih preskušanjih so se neželeni učinki ob nenadni prekinitvi zdravljenja pojavili pri približno 45 % bolnikov, ki so jemali zdravilo Duloxetine Lilly in pri 23 % bolnikov, ki so dobivali placebo.
In clinical trials among children and adolescents treated with other antidepressants, suicide-related behaviour (suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed compared to those treated with placebo (see section 4.2).
Samomorilno vedenje (poskuse samomora in samomorilne misli) ter sovražnost (predvsem napadalnost, nasprotovalno vedenje in jezo) so v kliničnih študijah pogosteje opažali pri otrocih ter mladostnikih, zdravljenih z drugimi antidepresivi, kot pri tistih, ki so jemali placebo (glejte poglavje 4.2).
In clinical trials and during marketed use, the frequency varies with patient population and dose regimens.
Pogostnost v klinicnih raziskavah in med uporabo, ko je insulin že na trgu, se spreminja glede na populacijo bolnikov in odmerne sheme.
In clinical trials and post-marketing experience, accidental or intentional acute overdose of aripiprazole alone was identified in adult patients with reported estimated doses up to 1,260 mg (41 times highest recommended daily aripiprazole dose) with no fatalities.
V kliničnih preskušanjih in iz izkušenj v obdobju trženja so ugotovili naključno ali namerno akutno preveliko odmerjanje aripiprazola samega pri odraslih bolnikih z ocenjenimi odmerki do 1.260 mg (41-kratnik najvišjega priporočenega dnevnega odmerka aripiprazola) brez smrtnih primerov.
In clinical trials approximately 5% of patients were treated at doses below 1.1 mg (1.5 mg of salt).
V kliničnih preizkušanjih so približno 5 % bolnikov zdravili z dnevnimi odmerki, manjšimi od 1,1 mg (1,5 mg soli).
In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain (see section 4.8).
V kliničnih preskušanjih niso ugotovili, da bi aripiprazol povzročil klinično pomembno povečanje telesne mase (glejte poglavje 4.8).
In clinical trials at the recommended dose (2 mg/kg), robenacoxib reduced pain and inflammation in dogs undergoing orthopaedic or soft tissue surgery.
Pri kliničnih poskusih je robenakoksib v priporočenem odmerku (2 mg/kg) zmanjšal bolečino in vnetje pri psih, podvrženih ortopedskim operativnim posegom in operativnim posegom na mehkih tkivih.
In clinical trials Cervarix has been shown to prevent HPV related diseases in women aged 15 years and older.
Klinična preskušanja so pokazala, da cepivo Cervarix pri ženskah, starih 15 let in več, prepreči pojav bolezni, ki so povezane s HPV.
In clinical trials Cetrotide was used with human menopausal gonadotropin (HMG), however, limited experience with recombinant follicule-stimulating hormone (FSH) suggested similar efficacy.
V kliničnih študijah so zdravilo Cetrotide uporabljali s humanim menopavznim gonadotropinom (HMG), vendar pa omejene izkušnje z rekombinantnim folikle stimulirajočim hormonom (FSH) kažejo podobno učinkovitost.
In clinical trials conducted in a broad range of indications and at a wide range of doses (from 6 MIU/m2/week in hairy cell leukaemia up to 100 MIU/m2/week in melanoma), the most commonly reported undesirable effects were fever, fatigue, headache and myalgia.
V kliničnih raziskavah, opravljenih pri širokem razponu indikacij in širokem razponu odmerkov (od 6 mio i.e./m2 na teden pri dlakastocelični levkemiji do največ 100 mio i.e./m2 na teden pri melanomu), so bili najpogosteje opaženi neželeni učinki zvišana telesna temperatura, utrujenost, glavobol in mialgija.
In clinical trials conducted in patients with CRF not on dialysis treated with epoetin alfa, the average duration of therapy was nearly five months.
V kliničnih preskušanjih, ki so jih opravili pri bolnikih s kronično ledvično odpovedjo, ki se še ne zdravijo z dializo, a se zdravijo z epoetinom alfa, je zdravljenje povprečno trajalo skoraj pet mesecev.
In clinical trials doses of up to 4 mg in monthly intervals have been used and isolated cases of overdoses with 8 mg occurred.
V kliničnih preskušanjih so uporabljali enkrat na mesec odmerke do 4 mg; v posameznih primerih pa je prišlo do prekomernega odmerjanja z odmerki po 8 mg.
In clinical trials elderly patients tend to titrate to a lower effective strength than patients less than 65 years of age.
V kliničnih preskušanjih so starejše bolnike običajno titrirali do nižje jakosti kot bolnike, mlajše od 65 let.
In clinical trials first degree AV block (PR prolongation > 220 msec) developed in 3% of patients within 2 hours of Rapiscan administration; transient second degree AV block with one dropped beat was observed in one patient receiving Rapiscan.
V kliničnih študijah se je v roku 2 ur po dajanju zdravila Rapiscan pri 3% bolnikov pojavil AV blok prve stopnje (podaljšanje intervala PR > 220 msek); prehodni AV blok druge stopnje z enim izpuščenim utripom so opazili pri enem bolniku, ki je prejel zdravilo Rapiscan.
In clinical trials for proliferating infantile haemangioma, the most frequently reported adverse reactions in infant treated with HEMANGIOL were sleep disorders, aggravated respiratory tract infections such as bronchitis and bronchiolitis associated with cough and fever, diarrhoea, and vomiting.
Pri kliničnih preizkušanjih hitro rastočega infantilnega hemangioma so bili neželeni učinki, o katerih so največkrat poročali pri dojenčkih, zdravljenih z zdravilom HEMANGIOL, motnje spanja, poslabšanje okužb dihalnih poti, kot sta bronhitis in bronhiolitis, povezana s kašljem in z vročino, driska in bruhanje.
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Aerius tablets were reported in 3 % of patients in excess of those treated with placebo.
V kliničnih preskušanjih pri različnih indikacijah za uporabo zdravila, vključno z alergijskim rinitisom in kronično idiopatsko urtikarijo, so pri priporočenem odmerku 5 mg na dan o neželenih učinkih zdravila Aerius poročali pri 3 % bolnikov več kot pri tistih, ki so bili zdravljeni s placebom.
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Azomyr tablets were reported in 3 % of patients in excess of those treated with placebo.
V kliničnih preskušanjih pri različnih indikacijah za uporabo zdravila, vključno z alergijskim rinitisom in kronično idiopatsko urtikarijo, so pri priporočenem odmerku 5 mg na dan o neželenih učinkih zdravila Azomyr poročali pri 3 % bolnikov več kot pri tistih, ki so bili zdravljeni s placebom.
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Azomyr were reported in 3 % of patients in excess of those treated with placebo.
V kliničnih preskušanjih pri različnih indikacijah za uporabo zdravila, vključno z alergijskim rinitisom in kronično idiopatsko urtikarijo so pri priporočenem odmerku 5 mg na dan o neželenih učinkih zdravila Azomyr poročali pri 3 % bolnikov več kot pri tistih, ki so bili zdravljeni s placebom.
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with desloratadine were reported in 3% of patients in excess of those treated with placebo.
V kliničnih preskušanjih pri različnih indikacijah, vključno z alergijskim rinitisom in kronično idiopatsko urtikarijo, so se neželeni učinki med uporabo priporočenega odmerka 5 mg na dan pojavili pri 3% več prejemnikov desloratadina kot prejemnikov placeba.